Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
Eli Lilly says experimental Alzheimer's drug reduces brain plaque in early study
10:21am, Wednesday, 05'th Apr 2023
Eli Lilly said a higher dose of the up-and-coming Alzheimer's treatment, remternetug, had a larger effect on clearing amyloid plaque.
2 Top Growth Stocks That Can Withstand an Economic Downturn
10:15am, Wednesday, 05'th Apr 2023
New data points to a looming recession in the U.S. In response, growth stocks took a step backward yesterday. Eli Lilly and Catalyst Pharmaceuticals are both capable of swimming against the current.
Why Lilly (LLY) Could Beat Earnings Estimates Again
01:42pm, Tuesday, 04'th Apr 2023
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
10:38am, Tuesday, 04'th Apr 2023
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Top Healthcare Stocks to Buy for April
09:12am, Tuesday, 04'th Apr 2023
Eli Lilly's promising diabetes drug Mounjaro could be an obesity-therapy blockbuster. Johnson & Johnson's consumer healthcare spinoff will make the company more profitable.
7 Spectacular Growth Stocks to Buy in April
06:52pm, Monday, 03'rd Apr 2023
Historically, investors looking for growth stocks to buy found the best opportunities during economic expansions, which generally coincided with lower interest rates. That was true of the most recent
3 Stocks That Could Benefit From the Ozempic Craze
09:45am, Thursday, 30'th Mar 2023
Novo Nordisk's business has been red-hot, thanks to soaring obesity-related revenue. Eli Lilly has its own promising weight-loss treatment which could be a game changer.
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
11:40pm, Wednesday, 29'th Mar 2023
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient po
Final trades: Intel, JPMorgan, Eli Lilly & Amgen
07:17pm, Wednesday, 29'th Mar 2023
The final trades of the week. With CNBC's Tyler Mathisen and the Fast Money traders, Steve Grasso, Courtney Garcia, Tim Seymour and Guy Adami.
Drugs for obesity are a massive market, says Mizuho's Jared Holz
06:59pm, Wednesday, 29'th Mar 2023
Jared Holz, Mizuho, joins 'Fast Money' to discuss obesity drugs with CNBC's Tyler Mathisen and the Fast Money traders.
3 Dividend Stocks That Have Been Paying Investors Since the 1800s
09:00am, Wednesday, 29'th Mar 2023
Eli Lilly, ExxonMobil, and the Toronto-Dominion Bank are all solid companies. Impressively, all three have been paying dividends for over 100 years.
Is Eli Lilly or Bristol Myers Squibb the Better Value Stock to Buy Right Now?
10:15am, Tuesday, 28'th Mar 2023
Big pharma stocks ought to perform well in the current high interest rate environment. Eli Lilly and Bristol Myers Squibb have long been top value plays.
Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker
10:17am, Monday, 27'th Mar 2023
Novartis stock surged Monday after the company's treatment reduced the risk of relapse in patients with early-stage breast cancer. The post Novartis Surges As It Goes After Eli Lilly's Second Biggest
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:57am, Monday, 27'th Mar 2023
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
02:37pm, Friday, 24'th Mar 2023
Novo Nordisk stock popped Friday after higher doses of its popular drug, semaglutide, led to greater weight loss in diabetes patients. The post The Ozempic Obesity Battle Is Heating Up With Novo Scori
